Key result
High-dose deferoxamine infusion reduced serum ferritin and improved ejection fraction, mitral E/A ratio, and left ventricular strain at 3 months.
Why the study?
To assess cardiac function and remodeling in children with thalassemia major after a high dose, short course of deferoxamine infusion using speckle echocardiography, and to evaluate this modality in early recognition of recovering myocardial dysfunction.
Does high dose deferoxamine infusion improve cardiac function and remodeling in children with beta-thalassemia major?
Cohort (n=21)
Does high dose deferoxamine infusion improve cardiac function and remodeling in children with beta-thalassemia major?
A short course of high-dose intravenous deferoxamine significantly improves echocardiographic markers of cardiac function and remodeling in children with beta-thalassemia major.
Answers are grounded in this paper and cite their sources.
Speckle tracking may detect early myocardial recovery after high-dose deferoxamine in thalassemia; leaves open clinical utility pending prospective trials.
Background: Speckle tracking echocardiography has great value in evaluation of regional and global myocardial function. Objectives: The goal of this study was an assessment of cardiac function and remodeling in children with thalassemia major after infusion of a high dose of deferoxamine during a short course by speckle echocardiography and evaluate the efficacy of this imaging modalities in the early recognition of recovering of myocardial dysfunction. Methods: In a prospective study between Feb 2014 till 2017 conventional 2 dimensional and speckle tracking echocardiography were done consecutively on 21 patients with beta-thalassemia major before intravenous infusion of high dose of deferoxamine (50 mg/kg) for 5 days and then after 3 months echocardiographic measurements repeated for assessment of efficacy of deferoxamine infusion on ventricular function and cardiac remodeling of our study population. Results: Serum ferritin of all patients reduced significantly (P < 0.001). Ejection fraction was improved after the therapy (P < 0.001). Mitral E/A velocity ratio after therapy increased significantly (P < 0.001). Strain imaging measures showed an increase in apical lateral, mid-lateral, basal lateral, mid-septal, basal septal left ventricular longitudinal wall strain three months after the use of high dose deferoxamine (P < 0.001). Apico-septal wall strain measurements of the left ventricle did not change significantly after high dose deferoxamine (P = 0.144). Conclusions: Intravenous infusion of high dose of deferoxamine after chelating of iron results in reduction of serum ferritin which may cause washout of cardiac deposit of iron with consequent improvement of cardiac function and remodeling.
No takes yet. Share an insight, caveat, or question.
Shahryari et al. (2019) conducted a cohort in beta-thalassemia major (n=21). Deferoxamine was evaluated on Serum ferritin, ejection fraction, mitral E/A velocity ratio, and left ventricular longitudinal wall strain (p=<0.001). High-dose deferoxamine infusion reduced serum ferritin and improved ejection fraction, mitral E/A ratio, and left ventricular strain at 3 months.
Synapse has enriched 10 related papers. Consider them for comparative context: